TrademarkDir
RIGHT RATIO FOR THE RIGHT PATIENT
DEAD

Serial Number

86400673

Owner

NEUROVANCE, INC.

Attorney

Michael P. Straher

Filing Date

Sep 19, 2014

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

RIGHT RATIO FOR THE RIGHT PATIENT Trademark

Serial Number: 86400673

RIGHT RATIO FOR THE RIGHT PATIENT is a trademark filed by NEUROVANCE, INC. on September 19, 2014. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

NEUROVANCE, INC. (4 trademarks)

43 Thorndike Street, Suite S1-3
Cambridge, MA 02141

Entity Type: 03

Trademark Details

Filing Date

September 19, 2014

Registration Date

Not Registered

Published for Opposition

February 10, 2015

Filing History

ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
May 14, 2018 MAB6
ABANDONMENT - NO USE STATEMENT FILED
May 14, 2018 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 28, 2017 EXRA
SOU EXTENSION 5 GRANTED
Oct 27, 2017 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 27, 2017 AITU
SOU EXTENSION 5 FILED
Oct 6, 2017 EXT5
SOU TEAS EXTENSION RECEIVED
Oct 6, 2017 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 11, 2017 EXRA
SOU EXTENSION 4 GRANTED
Apr 7, 2017 EX4G
SOU EXTENSION 4 FILED
Apr 7, 2017 EXT4
SOU TEAS EXTENSION RECEIVED
Apr 7, 2017 EEXT
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 10, 2017 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 10, 2017 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 8, 2016 EXRA
SOU EXTENSION 3 GRANTED
Nov 5, 2016 EX3G
SOU EXTENSION 3 FILED
Oct 7, 2016 EXT3
SOU TEAS EXTENSION RECEIVED
Oct 7, 2016 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 13, 2016 EXRA
SOU EXTENSION 2 GRANTED
May 12, 2016 EX2G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
May 11, 2016 AITU
SOU EXTENSION 2 FILED
Apr 7, 2016 EXT2
SOU TEAS EXTENSION RECEIVED
Apr 7, 2016 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 9, 2015 EXRA
SOU EXTENSION 1 GRANTED
Oct 7, 2015 EX1G
SOU EXTENSION 1 FILED
Oct 7, 2015 EXT1
SOU TEAS EXTENSION RECEIVED
Oct 7, 2015 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 7, 2015 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 10, 2015 NPUB
PUBLISHED FOR OPPOSITION
Feb 10, 2015 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 21, 2015 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 6, 2015 CNSA
ASSIGNED TO EXAMINER
Jan 5, 2015 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 29, 2014 NWOS
NEW APPLICATION ENTERED
Sep 23, 2014 NWAP

Related Trademarks

More from this Owner

CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT

CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT

CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT

CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT

NEUROVANCE

NEUROVANCE

CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT

CENTANAFADINE SR IS A NOREPINEPHRINE- AND DOPAMINE-PREFERRING TRIPLE REUPTAKE INHIBITOR THAT HAS THE RIGHT RATIO FOR THE RIGHT PATIENT